Effects of Triple Therapy on the Clinical Course of Non-Eosinophilic COPD Groups B.

BACKGROUND

Although the efficacy of triple therapy in treating chronic obstructive pulmonary disease (COPD) patients with a history of exacerbation is well established in groups with frequent exacerbations, less research has been conducted on its use in group B. Here, we investigated the effects of triple therapy on COPD patients with low eosinophil counts in the context of the current management of group B.

METHODS

Using data from the Korean COPD Subtype Study (KOCOSS), we selected patients with blood eosinophil count (BEC) less than 300 cells/μL as non-eosinophilic COPD groups. The study evaluated the effect of a triple therapy group (combination of inhaled corticosteroid, a long-acting β2-agonist [LABA] and a long-acting muscarinic antagonist [LAMA]) and a dual therapy group (LABA/LAMA) on moderate-to-severe exacerbations, as well as longitudinal changes in lung function over 3 years in patients categorized as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B.

RESULTS

Of the 328 non-eosinophilic COPD group B, 145 (44.2%) patients were in triple therapy and 183 (55.8%) patients were in dual therapy. Triple therapy group showed an increased risk of moderate-to-severe exacerbation in multivariate adjusted model (adjusted incidence rate ratio of annual rate, 2.04; 95% confidence interval, 1.45 to 2.84; < 0.001). Similarly, restricted cubic spline regression analysis of annual rates of moderate-to-severe exacerbations suggested an increased risk associated with the triple therapy over dual therapy in BEC lower than 300 cells/μL. There was no significant difference in the adjusted rate of forced expiratory volume in 1 second decline between triple therapy group and dual therapy group (-10.0 [-39.8 to -19.7] mL/year vs. 22.3 [-4.4 to -49.0] mL/year, for interaction = 0.888).

CONCLUSION

In conclusion, our research suggests that triple therapy was associated with a higher risk of moderate-to-severe exacerbations in non-eosinophilic COPD categorized as GOLD B compared with dual therapy.